oral tirzepatide clinical trial tirzepatide: what actually exists, what does not, and what is coming next Tirzepatide: First Approval | Drugs

In a significant milestone for type 2 diabetes care, Novo Nordisk has unveiled full results from its SOUL cardiovascular outcomes trial, confirming that oral semaglutide (14 mg) reduces the risk of major adverse cardiovascular events (MACE) by 14 per cent compared to placebo in adults with type 2 diabetes and existing cardiovascular and/or chronic kidney disease.The findings, presented at the American College of Cardiology's (ACC) Annual Scientific Session and Expo in Chicago, and simultaneously published in the New England Journal of Medicine, mark a major advancement in cardiometabolic treatment

2 in 1: electrolytes + ionic trace minerals for hydration and brain function.*

Even Halle Berry agrees.

Cooling: Temperature controlled with overheating protection

Take daily for all-in-one digestive support, muscle support, & a wellness boost

American culture encourages overconsumption, fueled by ubiquitous availability and pervasive marketing of ultra-processed foods and other addictive substances